
Hongming Huang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2248508/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The role of cystatin C in multiple myeloma. International Journal of Laboratory Hematology, 2022, 44, 135-141.	1.3	3
2	The Prognostic Role of Cyclin D1 in Multiple Myeloma: A Systematic Review and Meta-Analysis. Technology in Cancer Research and Treatment, 2022, 21, 153303382110652.	1.9	4
3	The Mutation of BTG2 Gene Predicts a Poor Outcome in Primary Testicular Diffuse Large B-Cell Lymphoma. Journal of Inflammation Research, 2022, Volume 15, 1757-1769.	3.5	8
4	CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients. Journal of Hematology and Oncology, 2021, 14, 90.	17.0	8
5	The role of cystatin C as a proteasome inhibitor in multiple myeloma. Hematology, 2020, 25, 457-463.	1.5	10
6	<p>Entire ABL1 Gene Deletion Without BCR/ABL1 Rearrangement in a Female Patient with B-Cell Precursor Acute Lymphoblastic Leukemia</p> . OncoTargets and Therapy, 2020, Volume 13, 783-790.	2.0	4
7	TBL1XR1 mutation predicts poor outcome in primary testicular diffuse large B-cell lymphoma patients. Biomarker Research, 2020, 8, 10.	6.8	10
8	IL-17A Increases Multiple Myeloma Cell Viability by Positively Regulating Syk Expression. Translational Oncology, 2019, 12, 1086-1091.	3.7	15
9	<p>Coexistence Of A Huge Venous Thromboembolism And Bleeding Tendency In Cytokine Release Syndrome During CAR-T Therapy</p> . OncoTargets and Therapy, 2019, Volume 12, 8955-8960.	2.0	8
10	Targeting the cross-talk between the hedgehog and NF-κB signaling pathways in multiple myeloma. Leukemia and Lymphoma, 2019, 60, 772-781.	1.3	16
11	Lenalidomide combined with R-GDP in a patient with refractory CD5-positive diffuse large B-cell lymphoma: A promising response and review. Cancer Biology and Therapy, 2018, 19, 549-553.	3.4	6
12	The effect of marrow stromal cells on TRAF6 expression levels in myeloma cells. Oncology Letters, 2017, 14, 1464-1470.	1.8	4
13	TRAF6 is required for BLyS-mediated NF-κB signaling in multiple myeloma cells. Medical Oncology, 2015, 32, 239.	2.5	4